Science1 publisher2 min readPublished
Jining team reassembles fragmented microbial gene clusters to rank drug candidates
Researchers at Jining Medical University rebuilt microbial gene clusters broken across contigs and tested six predicted compounds on seven cancer cell lines. The approach ranks leads from microbes no one can culture, though it only prioritizes and the structures and activity still need confirming.
The Scientist · Science desk
What happened
- Those fragments hold biosynthetic information that would be missed if each piece were analyzed on its own, the researchers found.
- Of the six compounds synthesized, D and E showed the most notable cytotoxic activity and the clearest differences across the seven cancer cell lines.
- The paper, led by first author Xiao Yang, appears in the journal Microbiology Spectrum.
Compiled by The ScientistSomething wrong?How this is made
Why it matters
- capability Clusters that assembly software would otherwise leave broken become reconstructable, so DNA from microbes no one can grow opens to drug prospecting.
- constraint The result is a ranked set of hypotheses. The authors say structures, activity and therapeutic value all still need experimental confirmation.
- decision Ranking candidates before synthesis points limited chemistry and assay effort toward the leads with the strongest basis.
The reconstruction works backward from clusters that are already understood. Biosynthetic gene clusters are groups of neighboring genes that together encode a single compound [2]. The team took clusters whose products had already been experimentally characterized, used them as reference maps, and searched large metagenomic data sets for related pieces of biosynthetic information [5]. Where those pieces came back broken across contigs, the researchers used the known clusters to fill in the missing pathway and predict what kind of molecule it might encode [6]. "We connected computational mining of metagenomic data with experimental validation," said Lei Zhang, a pharmaceutical engineering professor at Jining Medical University and the study's corresponding author [7][3].
The authors report that fragmented data can hold biosynthetic detail that would be missed if each fragment were analyzed separately [8]. "We chemically synthesized six candidate compounds and tested them across seven cancer cell lines," Zhang said, "with compounds D and E showing the most notable activity and clear differences among cancer cell lines" [9].
The study does not report potency figures for D and E, or how many predicted candidates the six were drawn from. The candidates were described as having potential antibacterial or anticancer activity, but the experimental work covered cancer cell lines only [1][9]. For anyone reading this as a path to new antibiotics, the antibacterial case here rests on computation.
"Fragmented metagenomic data should not simply be treated as incomplete or unusable," Zhang said [12]. Reconstruction and product prediction are prioritization steps; chemical structures, biological activities and therapeutic value still have to be established by experiment [11]. The authors also flag an open question beneath the whole exercise. "Further experiments are still needed to confirm their biological mechanisms, activity profiles and therapeutic potential, as well as whether predicted products are produced naturally by the corresponding microorganisms," Zhang said [13].
What to watch
- Whether follow-up experiments confirm the microbes actually make the predicted compounds in nature.
- Published potency and selectivity figures for compounds D and E.
- Whether the predicted antibacterial candidates get synthesized and tested, since only cancer cell lines were screened here.